 9. Patents included in the following specific risk groups that may influence safety and efficacy assessments at the discretion of the investigator:: septic arthtritis, rheumatic disease, gout, recurrent pseudogout, paget disease, joint fracture, alcaptonuria, acromegaly, hemochromatosis, wilsons disease, primary osteochondrosis, hereditary disorderex: hyperkinesia, collagen gene abnormality ,etc 